Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer

Wiener Klinische Wochenschrift

Volumn 128, Issue 17-18, 2016, Pages 635-640

  Kos, Mehmet ^a   Hocazade, Cemil ^b   Kos, F Tugba ^a   Uncu, Dogan ^b   Karakas, Esra ^b   Dogan, Mutlu ^b   Uncu, Hikmet Gulsen ^c   Yildirim, Nuriye ^b   Zengin, Nurullah ^b  

^a DUZCE UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Turkish Drug and Medical Device Institution   (Turkey)

Author keywords

Non small cell lung cancer; Platelet lymphocyte ratio; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER PROGNOSIS; DATA BASE; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREDICTION; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THROMBOCYTE COUNT; BLOOD; EPIDEMIOLOGY; LUNG TUMOR; MORTALITY; PATHOLOGY; PATIENT SELECTION; PLATELET COUNT; PREVALENCE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TURKEY (BIRD); VERY ELDERLY;

BIOLOGICAL MARKER;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET COUNT; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TURKEY;

EID: 84923668392     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-015-0724-8     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.
3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer statistics review 1975–2009 (Vintage: Populations). Bethesda: National Cancer Institute; 2009.
4. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005;23:175–83.
5. Li QQ, Lu ZH, Yang L, et al. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev. 2014;15:945–50.
6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
7. Pinedo HM, Verheul HMW, D’Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet. 1998;352:1775–7.
8. Peterson JE, Zurakowski D, Italiano JE Jr., et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15:265–73.
9. Liu HB, Gu XL, Ma XQ, et al. Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancer. Neoplasma. 2013;60:203–8.
10. Kim KH, Park TY, Lee JY, et al. Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci. 2014;29:507–11.
11. Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58.
12. Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466–72.
13. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011;13:499–503
14. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23:265–73.
15. Liu H, Wu Y, Wang Z, Yao Y, et al. Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis. 2013;5:783–9.
16. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev. 2013;14:5237–42.
17. Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer. 2014;110:1930–5.
18. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200:197–203.
19. Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012;17:216–22.
20. Sanchez-Lara K, Turcott JG, Juarez E, et al. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer. 2012;64:526–34.